Celgene Executive Chairman Bob Hugin retires
Fresh from its acquisition of Juno Therapeutics, Celgene announced that its Executive Chairman Bob Hugin was to retire effective 5 February, while Chief Executive Officer Mark Alles would step up to assume the additional role of Chairman of the Board of Directors.
The decision marks the end of Hugin’s 19 years at Celgene. Joining in 1999 as Chief Financial Officer and elected to the Board of Directors in 2001, he went on to take the role of President and Chief Operating Officer from 2006 to 2010, when he became the company’s Chief Executive Officer. In 2011, Hugin became Chairman, and Executive Chairman in 2016.
“Bob Hugin has contributed immeasurably to Celgene during his 19-year tenure. Under his stellar strategic leadership and guidance, Celgene has achieved unprecedented growth, produced extraordinary business results, and most importantly has developed and delivered transformational therapies for patients,” said Alles. “Bob is an inspirational leader, a mentor and a friend to everyone associated with the organisation. On behalf of all Celgene employees, we wish Bob and his family the best in the next chapter of his life.”
Michael D Casey, Celgene’s Lead Independent Director and Chairman of the Nominating, Governance & Compliance Committee, added: “During his time at Celgene, Bob delivered industry-leading results while driving the strategic direction of the company with the highest standards of character, values and integrity. As a nationally recognised health care expert, Bob has led efforts across the health care system to improve patient access and outcomes through the advancement of innovative science. We are grateful for Bob’s legacy of leadership through service and wish him well in his future pursuits. Mark is a tremendous leader and the best person to guide Celgene into its next phase of significant growth. Through his strategic leadership as CEO, Celgene has advanced and expanded its portfolio of potentially life-changing medicines.”
Under Hugin’s leadership, Celgene tripled in size form 2,500 employees in 2010 to 7,500, and more than two million patients were treated with one of the company’s medicines.
“It has been a tremendous privilege to be part of Celgene’s growth and to help advance Celgene’s mission to serve patients through scientific breakthroughs in the treatment of cancer and other serious medical conditions,” Hugin remarked. “I am thankful to my colleagues at Celgene, as well as to patient advocates, medical researchers and physicians across New Jersey and throughout the healthcare system for their collaboration in advancing this fundamentally important mission in the service of patients.”